An Open-label Study to Assess Brain Uptake and Safety of Flutemetamol F 18 Injection in Japanese Subjects With Probable Alzheimer's Disease, Subjects With Amnestic Mild Cognitive Impairment and Healthy Volunteers

Trial Profile

An Open-label Study to Assess Brain Uptake and Safety of Flutemetamol F 18 Injection in Japanese Subjects With Probable Alzheimer's Disease, Subjects With Amnestic Mild Cognitive Impairment and Healthy Volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Diagnostic use
  • Sponsors GE Healthcare
  • Most Recent Events

    • 01 Apr 2017 Results published in the Annals of Nuclear Medicine.
    • 07 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top